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evaluating HF patients, so that an OHT is offered 
only when it is expected to substantially improve 
the chances of survival or the quality of life, as 
compared with the medical therapy. Peak oxy‑
gen consumption (VO2) derived from cardiopul‑
monary exercise testing has been used for the se‑
lection of heart transplant candidates who are 
on optimal medical therapy. A peak VO2 of less 
than 12 to 14 ml/kg/min has been reported to be 
an independent predictor of 1 ‑year mortality and 
IntroductIon Orthotopic heart transplanta‑
tion (OHT) is an effective treatment for patients 
with end ‑stage heart failure (HF).1 An increas‑
ing number of ambulatory patients are placed 
on OHT waiting lists, while the supply of donor 
organs remains limited and is increasingly allot‑
ted to urgent transplantations. This has resulted 
in an extended waiting time and a higher mor‑
tality rate on the waiting list. Therefore, it plac‑
es enormous responsibility on transplant teams 
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AbstrAct
IntroductIon An increasing number of ambulatory patients are placed on orthotopic heart transplanta‑
tion (OHT) waiting lists, which results in an extended waiting time and a higher mortality rate.
objEctIvEs The aim of this study was to identify the factors associated with reduced survival during 
a 1 ‑year follow ‑up in patients with end ‑stage heart failure listed for an OHT.
PAtIEnts And mEthods We retrospectively analyzed the data of 221 adult patients, who were accepted 
for OHT in our institution over a 2 ‑year period between 2013 and 2014.
rEsuLts The mean (SD) age of the patients was 54.7 (9.6) years, and 90.1% of them were male. 
The mortality rate during the follow ‑up period was 43.3%. The modified Model for End ‑Stage Liver Disease 
(modMELD) score (odds ratio [OR], 1.70; P <0.001), as well as the plasma levels of high ‑sensitivity 
C ‑reactive protein (hs ‑CRP; OR, 1.10; P <0.01), sodium (OR, 0.74; P <0.001), and uric acid (UA; OR, 
1.003; P <0.05) were independent factors affecting death. The receiver ‑operating characteristic (ROC) 
analysis indicated that a modMELD cut ‑off of 10 (area under the ROC curve [AUC], 0.868; P <0.001), 
hs ‑CRP cut ‑off of 5.6 mg/l (AUC, 0.674; P <0.001), plasma sodium level cut ‑off of 135 mmol/l (AUC, 
0.778; P <0.001), and a plasma UA cut ‑off of 488 µmol/l (AUC, 0.634; P <0.001) were the most ac‑
curate factors affecting death.
concLusIons In conclusion, although limited to a single center, our study demonstrated that an elevated 
modMELD score, incorporating a combination of renal and hepatic laboratory parameters, as well as 
plasma sodium, UA, and hs ‑CRP levels at the time of listing are associated with reduced survival in 
ambulatory patients with end ‑stage heart failure, accepted for OHT.
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The Model for End ‑Stage Liver Disease (MELD) 
scoring system is used to evaluate both cardiore‑
nal and cardiohepatic interactions simultaneously. 
A number of studies have investigated the utility 
of the MELD score and its modifications as a pre‑
dictor of outcome in patients with HF.5‑8 The prog‑
nostic value of the standard MELD score calcu‑
lated using baseline plasma creatinine and bili‑
rubin levels as well as the international normal‑
ized ratio (INR) may be limited in patients re‑
ceiving warfarin.
In the  present study, we used a  modified 
MELD (modMELD) score, which is identical to 
the standard MELD score, except for the substi‑
tution of the INR with albumin, a protein pro‑
duced by the liver.8 The modMELD score elimi‑
nates the confounding effect of anticoagulation 
in the analyzed group of patients. The aim of this 
study was to determine the association between 
the individual modMELD score and 1‑year sur‑
vival in ambulatory patients with end ‑stage HF 
listed for OHT. Moreover, we aimed to identify 
additional risk factors of death during the 1 ‑year 
follow ‑up in this group of patients.
PAtIEnts And mEthods The study was a retro‑
spective review of the clinical records of 328 adult 
patients, who were put on the OHT waiting list 
in our institution between January 1, 2013, and 
December 31, 2014.
The study included ambulatory patients who 
died after inclusion on the transplant waiting 
list or survived 1 year on the waiting list. All in‑
cluded patients were treated in accordance with 
the guidelines of the European Society of Car‑
diology at the time of inclusion on the waiting 
list.9 They were on optimal medical therapy as 
well as defibrillation therapy with or without re‑
synchronization therapy. Only initial listing epi‑
sodes were included. Repeated episodes of listing 
for any reason were excluded from the analysis.
Patients who underwent OHT (n = 58) during 
the follow ‑up and patients awaiting heart trans‑
plantation with the “urgent status” because of 
inotropic support (n = 16) or mechanical circula‑
tory support at the time of listing were exclud‑
ed from the study, resulting in a study sample of 
221 participants.
As an indicator of multiorgan dysfunction, 
we calculated the modMELD score. In place of 
the INR, a conditional value was used calculat‑
ed as the difference between the plasma albu‑
min and normal albumin (4.1 g/dl) level. There‑
fore, if the plasma albumin level was higher 
than 4.1 g/dl, then the modMELD score was cal‑
culated as follows: 1.12 × (ln 1) + 0.378 × (ln to‑
tal bilirubin, in mg/dl) + 0.957 × (ln creatinine) 
+ 0.643. If the plasma albumin level was less than 
4.1 g/dl, then the modMELD score was calculat‑
ed as 1.12 × (ln [1 + 4.1 – albumin)]) + 0.378 × (ln 
total bilirubin) + 0.957 × (ln creatinine) + 0.643.
A lower limit was 1.0 for all variables and the 
upper limit for creatinine was capped at 4.0 mg/dl. 
There was no upper limit for bilirubin and albumin. 
is widely used as a cut ‑off for heart transplant 
listing. However, peak VO2 may be influenced by 
multiple factors such as age, sex, motivation, ane‑
mia, lung function, body weight, skeletal muscle 
strength, and peripheral circulation.2
There are 2 other risk stratification tools that are 
often used to predict the prognosis of patients with 
end ‑stage HF: the Heart Failure Survival Score and 
the Seattle Heart Failure Score.3,4 These prediction 
tools fail to adequately address the impact of oth‑
er organ dysfunctions. Patients with end ‑stage HF 
can develop varying degrees of hepatic dysfunc‑
tion due to congestive hepatopathy and reduced 
hepatic blood flow. Renal dysfunction occurs in 
these patients as a consequence of reduced cardi‑
ac output and decreased renal perfusion, accompa‑
nied by sodium and water retention. The use of di‑
uretics and angiotensin ‑converting enzyme inhib‑
itors can also contribute to worsening renal failure.
tAbLE 1 Baseline characteristics by survival and death
Parameter Survival
n = 125 (57%)
Death
n = 96 (43%)
P value
Age, y 58 (50–61) 56 (52–60) 0.8
BMI, kg/m2 28.1 (4.6) 25.9 (4.4) <0.001
Mean PAP, mmHg 23 (16–32) 28 (22.5–36) <0.001
Mean RAP, mmHg 5 (3–9) 5 (3–9) 0.9
TPG, mmHg 8 (7–10) 10 (6–14) 0.04
CI, l/min/m2 2.26 (1.9–2.5) 2.1 (1.8–2.4) 0.02
PVR, Wood units 1.9 (1.5–2.4) 2.4 (1.8–3.4) <0.001
LVEF, % 20.0 (18.0–25.0) 20.0 (16.5–24.0) 0.4
LA, mm 48.0 (43.0–55.0) 50.0 (45.5–57.0) 0.07
RVEDd, mm 30 (28–34) 33 (30–37.5) <0.001
Peak VO2, ml//kg/min 12.8 (10.9–15.4) 10.2 (9–12.2) <0.001
modMELD score 7.9 (6.4–9.9) 12.8 (10.4–15.3) <0.001
Creatinine, µmol/l 90.0 (77.0–103.0) 110.0 (83.0–138.5) <0.001
Bilirubin, µmol/l 14.5 (10.1–22.4) 25.3 (16.0–37.3) <0.001
AST, U/l 24.0 (20.0–31.0) 25.0 (21.0–30,5) 0.7
ALT, U/l 22.0 (18.0–32.0) 20.0 (14.0–29.0) 0.01
Alkaline phosphatase, U/l 82.0 (63.0–110.0) 84.0 (63.0–125.0) 0.4
GGTP, U/l 72.0 (34.0–146.0) 86.0 (51.5–164.0) 0.1
Cholesterol, mmol/l 3.91 (3.28–4.96) 3.93 (3.25–4.93) 0.8
Triglycerides, mmol/l 1.29 (0.90–1.96) 1.07 (0.79–1.48) 0.006
Sodium, mmol/l 136 (135–138) 133 (131–135) <0.001
Fibrinogen, mg/dl 367 (308–416) 422.5 (351.5–544.5) <0.001
UA, µmol/l 443 (359–528) 506.5 (432–609.5) <0.001
hs ‑CRP, mg/l 3.0 (1.3–5.8) 6 (2.7–12.4) <0.001
NT ‑proBNP, pg/ml 2624 (1180–4770) 4322 (2501.5–8326) <0.001
Hematocrit, % 0.41 (0.04) 0.40 (0.05) 0.2
Hemoglobin, mmol/l 8.7 (1.0) 8.46 (1.1) 0.09
Values are expressed as mean (SD) or median (25th–75th percentile).
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, 
body mass index; CI, cardiac index; hs ‑CRP, high ‑sensitivity C ‑reactive protein; 
modMELD, modified Model of End ‑Stage Liver Disease; NT ‑proBNP, N ‑terminal pro‑
‑B‑type natriuretic peptide; VO2, oxygen consumption; PAP, pulmonary artery pressure, 
PVR, pulmonary vascular resistance; RAP, right atrial pressure; RVEDd, right ventricular 
end ‑diastolic diameter (M ‑mode); TPG, transpulmonary pressure gradient; UA, uric acid
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skewed; categorical variables were expressed as 
percentages.
Continuous variables were compared using 
an independent ‑sample t test, and categorical 
variables were compared using the χ2 test. A uni‑
variate logistic regression analysis was used to se‑
lect the potential independent predictive factors 
of death for inclusion in the multivariate analy‑
sis. The examined covariables included laborato‑
ry parameters (modMELD score and plasma sodi‑
um, UA, fibrinogen, hs ‑CRP, and N ‑terminal pro‑
‑B‑type natriuretic peptide [NT ‑proBNP] concen‑
trations), right ventricular end ‑diastolic dimen‑
sion, body mass index, transpulmonary gradient, 
and cardiac index. Univariate predictors of death 
with a P value of less than 0.2 were entered into 
a multivariate logistic regression model with step‑
wise backward elimination. The correlation be‑
tween explanatory variables was checked, and 
multicollinearity was evaluated by means of tol‑
erance and variance inflation factor. The C ‑statis‑
tic, Deviance, and Pearson goodness ‑of ‑fit statis‑
tics, as well as Hosmer –Lemeshow test for the fi‑
nal model were calculated. Differences were con‑
sidered statistically significant at a P value of less 
than 0.05. The results were presented as odds ra‑
tios (ORs) with 95% CIs. Receiver operator charac‑
teristic (ROC) curves were plotted and the Youden 
index was used to determine the cut ‑off for pa‑
rameters that were significant in the multivariate 
analysis. The results were presented as an area un‑
der the ROC curves (AUC), sensitivity, and speci‑
ficity with 95% CIs and significance levels.
rEsuLts Our analysis encompassed 221 am‑
bulatory patients with HF in New York Heart 
Association (NYHA) classes III (20.8%) and 
IV (79.2%), and with an Interagency Registry 
for Mechanically Assisted Circulatory Support 
(INTERMACS) score of 4–6, who were accepted 
on the waiting list between January 1, 2013, and 
December 31, 2014.
Baseline demographic, clinical, and laborato‑
ry characteristics by survival and death are sum‑
marized in tAbLE 1, while baseline medical thera‑
py and electrotherapy by survival and death—in 
tAbLE 2. During 1 ‑year follow ‑up, 96 patients (43%) 
died. The multivariate stepwise logistic regression 
analysis confirmed that the modMELD score and 
plasma hs ‑CRP, sodium, and UA concentrations 
were significant independent factors affecting 
death (tAbLE 3). The AUC indicated a good discrim‑
inatory power of the modMELD score as well as 
plasma hs ‑CRP, sodium, and UA concentrations 
in the prediction of death (tAbLE 4, FIGurEs 1 –4).
dIscussIon Based on a single ‑center study, 
we found that the elevation in the modMELD 
score—an objective numerical score obtained by 
inserting the values of plasma total bilirubin, al‑
bumin, and creatinine into a logarithmic formu‑
la—could reliably identify patients with end ‑stage 
HF at a higher risk for reduced survival during 
the 1 ‑year follow ‑up. The main advantage of this 
As with the standard MELD score, these raw 
scores were multiplied by 10 and rounded to 
the nearest integer.8
Laboratory data for the calculation of the mod‑
MELD score, as well as other data, were obtained 
at the time of inclusion on the transplant wait‑
ing list. Liver function parameters and plasma 
uric acid (UA), sodium, and C ‑reactive protein 
(CRP) levels were determined using the COBAS 
Integra 800 analyzer (Roche Instrument Center 
AG, Rotkreuz, Switzerland), in accordance with 
the manufacturer’s instructions. A highly sensi‑
tive latex ‑based immunoassay was used to detect 
the plasma CRP concentration. High ‑sensitivity 
CRP (hs ‑CRP) concentrations were determined 
with a standard detection limit of 0.0175 mg/dl. 
The follow ‑up survey by a chart review and tele‑
phone contact was performed in all patients at the 
end of the 1 ‑year follow ‑up.
statistical analysis The statistical analysis was 
performed using the  SAS software, version 
9.4 (SAS Institute Inc., Cary, North Carolina, 
United States). Continuous variables were ex‑
pressed as the mean (SD) if normally distribut‑
ed, or as the median (25th–75th percentile) if 
tAbLE 2 Baseline medical therapy and electrotherapy by survival and death
Parameter Survival
n = 125 (57%)
Death
n = 96 (43%)
P value
β ‑blockers 109 (87.2) 90 (93.6) 0.11
ACEIs 117 (93.6) 95 (99) 0.05
ARBs 8 (6.4) 1 (1.04) 0.05
Aldosterone antagonists 117 (93.6) 93 (96.9) 0.27
Digoxin 44 (35.2) 41 (42.5) 0.26
Diuretics 119 (95.2) 91 (94.8) 0.89
Statins 82 (65.6) 38 (39.6) 0.51
Warfarin/acenocoumarol 55 (44) 38 (39.6) 0.50
Aspirin 55 (44) 51 (53.1) 0.18
ICD 84 (67.2) 53 (55.2) 0.07
CRT ‑D 38 (30.4) 37 (38.5) 0.21
Data are presented as number (percentage) of patients.
Abbreviations: ACEIs, angiotensin ‑converting enzyme inhibitors; ARBs, angiotensin ‑II 
receptor blockers; CRT ‑D, cardiac resynchronization therapy with defibrillator; ICD, 
implantable cardioverter–defibrillator
tAbLE 3 Prognostic factors for death in a multivariate stepwise logistic regression 
analysis
Factor OR 95% CI P value
modMELD 1.70 1.45–1.99 <0.001
hs ‑CRP, mg/l 1.10 1.03–1.16 <0.01
Sodium, mmol/l 0.74 0.65–0.84 <0.001
Uric acid, µmol/l 1.03 1.00–1.06 <0.05
Goodness of fit: C ‑statistic, 0.91; Deviance, P = 0.99; Pearson χ2, P = 0.89; 
Hosmer–Lemeshow, P = 0.98
Abbreviations: OR, odds ratio; others, see tAbLE 1
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the group of patients with a higher modMELD 
score (>20), it is necessary to conduct a careful 
selection, because these patients show a high 
risk of death while waiting for and after the heart 
transplant.
Our study showed that decreased plasma so‑
dium concentrations were an independent risk 
factor for death in ambulatory patients await‑
ing an OHT. In our previous study, we found 
that a plasma sodium concentration measured 
in patients with end ‑stage HF directly before 
the OHT may be used to estimate the postoper‑
ative risk in heart transplant recipients during 
1 ‑year follow ‑up.14 Importantly, hyponatremia 
is one of the most powerful predictors of mor‑
tality in different populations of patients with 
HF.14‑16 Moreover, it was shown to be an indepen‑
dent variable in numerous prognostic models for 
outpatients with HF.4,17‑19
An increased plasma UA concentration was an‑
other independent factor that increased the risk 
of death in our patients. In patients with ad‑
vanced HF, elevated UA levels are associated with 
high morbidity and mortality rates.16,20 Wheth‑
er UA is only a marker of poor prognosis or is 
an active participant in the pathogenesis of HF 
is currently unknown. The mechanism of hyper‑
uricemia is complex and consists in an increased 
production due to the upregulation of xanthine 
oxidase and a decreased excretion due to renal 
insufficiency, which can be a consequence of car‑
diorenal syndrome and renal congestion.21 Recent‑
ly, it was reported that the association between 
UA levels and poor outcome in patients with HF 
was significant only when hyperuricemia was 
a marker of increased xanthine oxidase activity 
and not a consequence of decreased renal excre‑
tion in chronic kidney disease.22 The sources of UA 
are the liver and endothelium. Therefore, UA pro‑
duced in hypoxic states originates from endothe‑
lial cells, and hyperuricemia in HF patients may 
reflect the metabolic effect of hypoxia on the mi‑
crovasculature. Impaired oxidative metabolism 
due to enhanced reactive oxygen species release 
is the reason for the development of myocardial 
fibrosis, hypertrophy, left ventricular remodeling, 
and contractility impairment responsible for de‑
creased cardiac function. Moreover, UA has anti‑
oxidant properties and could protect against oxi‑
dative stress and oxidative injury.22
In this study, we found that an elevated plas‑
ma hs ‑CRP concentration is another indepen‑
dent predictor of death. This acute ‑phase reactant 
scoring system is its low cost and the common 
availability of the analyzed parameters.
It is a well ‑known fact that end ‑stage HF ad‑
versely affects other organs, especially the kid‑
neys and the liver. Hypervolemia and the trans‑
mission of venous congestion to the renal veins 
impair the glomerular filtration rate by reducing 
the glomerular net filtration pressure.10 Hepatopa‑
thy secondary to chronic HF may result in hypoal‑
buminemia and cholestatic changes, with an often 
increased plasma bilirubin level.11,12 The above pa‑
rameters are elements of the modMELD score sys‑
tem. Hypoalbuminemia is associated with a signif‑
icantly increased 1 ‑year mortality and increased 
risk of an urgent OHT in patients with symptoms 
of NYHA classes III and IV.11
Single ‑center studies have described higher 
rates of death and hospitalization due to HF ex‑
acerbation in patients with an increased bilirubin 
level.12 We identified only 2 publications discuss‑
ing the prognostic value of the modMELD score 
in the group of patients with advanced HF. In a 
retrospective study, Kato et al13 assessed the data 
of 151 ambulatory patients on optimal medical 
therapy and defibrillation therapy with or with‑
out resynchronization therapy. The population an‑
alyzed in this study differed from ours, because 
it included patients who underwent heart trans‑
plant evaluation. In addition, the modMELD cut‑
‑off value was higher than in our study and was 
part of a risk stratification model, which had been 
created in this analysis and consisted of peak 
VO2, modMELD, right ventricular stroke work 
index, and pulmonary capillary wedge pressure. 
Based on their study, the authors demonstrated 
that this model could discriminate between pa‑
tients with a high risk of death at 1 year, ventric‑
ular assist device implantation, or OHT. Interpre‑
tation of these results should allow for the fact 
that the United States differ from Poland with 
respect to the care of ambulatory patients with 
end ‑stage HF.
In a single ‑center retrospective study, Chok‑
shi et al8 found that the modMELD score of more 
than 20 predicts a significantly higher mortali‑
ty rate after OHT compared with the modMELD 
score below this value. The results of our study, 
together with the analysis by Chokshi et al,8 sug‑
gest that patients on the transplant waiting list 
with a modMELD score fluctuating between 10 
and 20 are at an increased risk of death during 
the subsequent 12 months, and they should un‑
dergo an OHT as soon as possible. However, in 
tAbLE 4 Receiver operating characteristic curves analysis
Parameter P value AUC 95% CI Cut ‑off Sensitivity 95% CI Specificity 95% CI
modMELD <0.001 0.868 0.821–0.915 10 0.82 0.73–0.89 0.77 0.68–0.84
hs ‑CRP, mg/l <0.001 0.674 0.603–0.746 5.6 0.56 0.46–0.66 0.73 0.64–0.80
Sodium, mmol/l <0.001 0.778 0.717–0.839 135 0.84 0.75–0.91 0.64 0.55–0.72
UA, µmol/l <0.001 0.634 0.561–0.708 488 0.59 0.49–0.69 0.66 0.57–0.74
Abbreviations: AUC, area under the receiver characteristic operating curves; others, see tAbLE 1
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response may be involved in HF through modifi‑
cation in the sympathetic and renin –angiotensin–
aldosterone systems. Moreover, hs ‑CRP is directly 
involved in HF because it can cause cell apoptosis, 
ventricular dysfunction, and impaired function 
protein is a nonspecific biochemical marker for 
inflammation, which is a key process in the de‑
velopment and progression of chronic HF. Ele‑
vated levels of hs ‑CRP have been observed in pa‑
tients with HF, and the activation of the immune 
FIGurE 1 Receiver 
operating characteristic 






































FIGurE 2 Receiver 
operating characteristic 
curve for uric acid
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and lasted 4 years, while the plasma hs ‑CRP cut‑
‑off value was lower than in the present study. We 
found that the plasma hs ‑CRP level was an in‑
dependent factor for death during the follow‑
‑up. Li et al25 analyzed patients in NYHA classes 
of organs other than the heart.23 The prognostic 
role of hs ‑CRP in the current study is in agree‑
ment with our previous analysis conducted in pa‑
tients with HF evaluated for a heart transplant.24 
In our previous study, the follow ‑up was longer 
FIGurE 4 Receiver 
operating characteristic 






































FIGurE 3 Receiver 
operating characteristic 
curve for the modified 
Model of End ‑Stage Liver 
Disease score
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III and IV with left ventricular dysfunction and 
demonstrated that mortality rates were higher in 
patients with hs ‑CRP levels exceeding 3.90 mg/l 
compared with patients with hs ‑CRP levels be‑
low this value.
study limitations The present study has a number 
of limitations, which mostly arose from its single‑
‑center and retrospective design and the limit‑
ed sample size. Owing to a small number of en‑
rolled patients, the number of variables included 
in the univariate analysis had to be limited. More‑
over, our patients underwent symptom ‑limited 
cardiopulmonary exercise testing, with the goal 
of achieving respiratory gas ‑exchange ratio ex‑
ceeding 1. Some patients could not reach this 
value, but we used their data as their best effort.
It is necessary to comment on the  lack of 
an independent prognostic value of the well‑
‑established predictor of outcomes in patients 
with HF, namely, NT ‑proBNP, in our study group. 
We found a strong positive correlation between 
the NT ‑proBNP level and modMELD score. This 
correlation made it impossible to include both 
those parameters in the multivariate logistic re‑
gression model.
Although we collected comprehensive informa‑
tion on candidates at the time of listing, as well as 
information regarding the mortality rate, limited 
data were gathered when the patient was removed 
from the waiting list. Specifically, information re‑
garding the proportions of patients removed from 
the waiting list because of improvement, deteri‑
oration, or withdrawal of consent were not ana‑
lyzed. We were able to analyze only survival data 
after removal from the waiting list. Because no 
clinical data on such patients were available, we 
were unable to comment on the follow ‑up thera‑
py and morbidities after removal from the waiting 
list. Moreover, we were not able to analyze clini‑
cal data of patients whose status had changed to 
the “urgent status”.
conclusions Although limited to a single center, 
our study demonstrated that an elevated mod‑
MELD score, incorporating a combination of re‑
nal and hepatic laboratory parameters, as well as 
plasma sodium, UA, and hs ‑CRP concentrations 
are associated with reduced survival in ambulato‑
ry patients with end ‑stage HF accepted for OHT.
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